Story
Avita Medical Stock Surges on Record Revenue and Raised Full-Year Guidance

Shares of Avita Medical (RCEL) surged more than 20% in pre-market trading after the regenerative medicine company announced record quarterly results and an upgraded financial outlook, signaling strong commercial momentum.
Record Quarter and Upgraded Outlook
Avita Medical reported second-quarter revenue of $21.7 million, an 18% increase year-over-year that beat analyst consensus estimates by approximately 8%. The company also posted a narrower-than-expected adjusted loss per share of $0.25, compared to the consensus forecast of a $0.30 loss.
Buoyed by the strong performance, management raised its full-year 2026 revenue guidance. The company now expects revenue to be in the range of $86 million to $89 million, a significant increase from its prior forecast of $80 million to $85 million. Avita also reaffirmed its goal of achieving cash flow breakeven in the fourth quarter of 2026.
Analyst Upgrade Adds to Momentum
The strong earnings report was followed by an analyst upgrade from BTIG, which raised its rating on Avita Medical stock from Neutral to Buy and set a price target of $7.00. The firm cited the company's improved execution and the record quarterly revenue beat as key reasons for the upgrade.
AdThis combination of a top- and bottom-line earnings beat, a material guidance increase, and a timely analyst endorsement created a powerful set of catalysts for the stock. The move was specific to the company, as the broader S&P 500 and NASDAQ indexes showed only modest gains.
Operational Drivers
On an earnings call, CEO Cary Vance noted that reimbursement uncertainty, a headwind in the previous year, has been progressively resolved through work with Medicare Administrative Contractors. The company's key commercial products, including RECELL, demonstrated strong sequential growth during the quarter.
This performance reinforces investor confidence in the company's commercial execution, which had been a point of concern in prior periods. Management anticipates that coding changes expected in 2027 will further reduce friction for healthcare providers using its products.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.